Neuro(b)log For Patients

Whenever I mention the possibility of prescribing medical cannabis to a patient in my clinic, I am instantly met with a wall of myths. These prejudices are deeply rooted not only among the general public but, surprisingly, among physicians themselves. Yet, in the Czech Republic, the legal prescription of medical cannabis has been possible since 2015. Most people still picture someone smoking marijuana on the street rather than a precisely dosed pharmaceutical. Patients' imaginations run wild, bringing up memories of the euphorigenic effects they might have experienced firsthand during their younger years, or triggering an intense fear of overdosing and losing control. The reality of modern neurology, however, is entirely different. Legal medical cannabis, cultivated under the strictest laboratory conditions, is processed by master pharmacists directly in pharmacies. They prepare it into precisely dosed oral capsules or specialized topical ointments for external use. 

This extemporaneous medicinal product (known as an IPLP in the Czech system) is compounded based on a magistraliter prescription – meaning a recipe with precise instructions from a doctor, exactly like custom eye drops or dermatological ointments. Both the physician and the pharmacist know precisely which strain the dry flower or extract comes from, the exact percentage of THC and CBD, and that the medication contains zero preservatives. For individuals in whom conventional treatment has failed or triggered intolerable side effects, this is often a literal lifeline. Let us put dogmas aside, look at the science, and explain how this plant truly interacts with our bodies.

How Cannabis Rewires the Chemistry of the Brain

In my previous article "Cannabis: What It Contains", we discussed the biochemical foundation of the plant and introduced the term endocannabinoidome. To view cannabis merely as a crude "natural analgesic" that numbly dampens pain would be a fatal mistake. The actual role of the endocannabinoid system (ECS) is to maintain a dynamic internal balance (homeostasis) across all systems of the human body – whether we are talking about the nervous, endocrine, or immune systems.

Endocannabinoid receptors (CB1 and CB2) are densely distributed throughout both the central and peripheral nervous systems, and plant-derived phytocannabinoids bind to them like a precise key into a lock. Today, science undeniably confirms that the ECS fundamentally modulates neurotransmitter release and directly influences neuroplasticity, which is the very foundation of learning.

Neuroplasticity is the brain's ability to alter its structure, forge new connections between neurons, and adapt to new situations. It takes place throughout a person's entire life, and we utilize it heavily during the rehabilitation of stroke patients. Cannabis changes the actual chemistry of the nervous system and clears the field so that the brain can effectively regenerate.

The Axis of Exercise and Inflammation: The Kynurenine Pathway 

Under the MicroscopeIt is a well-known fact that regular exercise is beneficial for the heart, weight loss, mental health, cognitive functions, and the overall prognosis of oncological patients. What few people outside the scientific community know, however, is how deeply physical activity alters the biochemistry of the brain itself. During regular exercise, the body metabolizes endocannabinoid and kynurenine metabolites, whose production is tightly interconnected through the activation of CB1 and CB2 receptors.

The kynurenine pathway is the primary biochemical highway through which the human body breaks down tryptophan, an essential amino acid. While a smaller fraction of tryptophan is converted into serotonin (the "good mood" hormone) and melatonin (the sleep hormone), a massive 95% of tryptophan travels down the kynurenine pathway. This pathway serves as a critical bridge between the immune system, chronic inflammation, and the destruction of brain cells.When the body is healthy and balanced, this pathway primarily produces kynurenic acid (KYNA). This molecule acts as an ultimate biochemical shield for the brain – protecting neurons from overexcitation, dampening the toxic effects of glutamate, and exerting potent anti-inflammatory properties.

What happens, though, when this system fails in the brain and nerves due to disease?

Upon the onset of a neurological disease, nerve cells (neurons) under the influence of inflammation begin to uncontrollably flood the brain with glutamate – the primary excitatory neurotransmitter. Its excess triggers a phenomenon known as excitotoxicity, a state where cells become overstimulated to the point of burnout and death. This is where medical cannabis steps in for its first crucial intervention: activated CB1 receptors function as an uncompromising "retrograde brake." Phytocannabinoids (THC and CBD) bind to these receptors and send a signal backward to the preceding neuron, commanding it to immediately halt the release of glutamate. By doing so, cannabis shields the brain from destruction (neuroprotection).

As soon as chronic inflammation takes root in the body (which is a hallmark feature of multiple sclerosis, Parkinson's disease, depression, or chronic pain), immune cells activate a specific enzyme called IDO. This enzyme literally hijacks and reroutes the kynurenine pathway, splitting the tryptophan molecule apart. Instead of the protective shield, the body starts massively churning out quinolinic acid (QUIN). QUIN is a potent toxin to the brain: it overexcites NMDA receptors, causes massive oxidative stress, damages mitochondria, and unleashes excitotoxicity, driving brain cells to literally "excite themselves" to death.

Furthermore, because inflammation consumes all available tryptophan to manufacture this neurotoxin, the body is left with an absolute deficit of raw materials needed to produce serotonin and melatonin. This is why chronic inflammation in neurology is so frequently accompanied by severe insomnia, anxiety, and depression – symptoms routinely seen in patients suffering from strokes, multiple sclerosis, or neurodegenerative conditions like Parkinson's and Alzheimer's disease.

However, groundbreaking research (such as studies in the prestigious journal Pharmaceuticals, 2023) demonstrates that the endocannabinoid system can regulate the kynurenine pathway. When medical cannabis is administered, it activates CB1 and CB2 receptors, which act as an internal brake on inflammation. Cannabis blocks the production of neurotoxic quinolinic acid and instead promotes the synthesis of protective kynurenic acid. Simply put: Cannabis shifts the kynurenine pathway back into its "brain protection" mode and shuts down toxic neuroinflammation.

From Biochemistry to the Patient: How Cannabis Targets Specific Symptoms

In my clinical practice, I utilize these targeted biochemical mechanisms to bring tangible relief to patients facing debilitating neurological conditions:

• Neuropathic Pain: In patients suffering from diabetic polyneuropathy, post-herpetic neuralgia (severe pain following shingles), or trigeminal neuralgia, damaged nerves continuously fire false pain signals to the brain. Cannabinoids target CB2 receptors directly on these peripheral nerves as well as TRPV1 receptors. For the patient, this means the burning, stabbing pain recedes into the background and becomes manageable.
• Spasticity and Muscle Spasms in Multiple Sclerosis: Due to the destruction of myelin sheaths, nerve impulses in the spinal cord and brain short-circuit. Muscles fail to receive the signal to relax, leaving them in constant tension. The result is painful stiffness (spasticity) and severe cramps. By lowering glutamate levels and modulating GABA transmissions (the brain's primary inhibitory neurotransmitter), THC and CBD ease this pathological muscle tension, making the pain far more bearable and restoring mobility.
• Post-Stroke Spasticity (Post-Ictal Spasticity): Whether a stroke is ischemic (caused by a blocked vessel) or hemorrhagic (caused by bleeding into brain tissue), damage to the brain's motor pathways often results in a total loss of muscle control. The brain loses its capacity to send inhibitory, relaxing signals; consequently, muscles on the affected side of the body enter a state of permanent, painful contraction (resulting in a clenched hand or a rigid leg). This stiffness severely paralyzes daily activities and halts physical therapy. This is where the triple myorelaxant effect of phytocannabinoids, driven by the THC content, proves invaluable:
  1. The combination of THC and CBD works at the level of the spinal cord and brainstem, restoring the delicate equilibrium between glutamate and GABA. Finding the precise ratio of THC to CBD is key to achieving optimal clinical efficacy.
  2. Once cannabis relaxes the muscles and dampens the pain, the patient gains a vital "therapeutic window" to engage in effective stretching and physical exercises, allowing neuroplasticity to finally begin its work.
  3. Safe profile for polymorbid patients: Unlike conventional muscle relaxants, which frequently cause severe sedation, confusion, or generalized muscle weakness (even on the unaffected side of the body) in elderly stroke survivors, medical cannabis can be finely titrated. It relieves spastic muscles without stripping the patient of the alertness and cognitive energy needed for active rehabilitation.
  4. It must be noted that the effect of cannabis is temporary, strictly dependent on the specific THC:CBD ratio, and cannot completely eradicate long-standing structural spasticity.
• Insomnia: When inflammation depletes tryptophan to create neurotoxins, the body is left without the chemical precursor for melatonin. Cannabis blocks this inflammatory drain, restoring natural melatonin production. Furthermore, through interaction with receptors in the hypothalamus, it helps patients fall asleep faster, prolongs deep sleep phases (NREM), and suppresses the nocturnal pain that would otherwise wake them.
• Supporting Neuroplasticity: Chronic inflammation and oxidative stress completely paralyze the brain's innate capacity to repair itself. Research into CBD within regenerative medicine demonstrates that by suppressing inflammatory cytokines, cannabinoids effectively clean the "cellular terrain" in brain tissue, creating the ideal biological environment for neural adaptation, regeneration, and the forging of new pathways.

Resetting the Trigeminal Nerve: How Cannabis Halts the Electrical Storms of Migraine

Migraine and chronic headaches are not merely simple reactions to muscle tension or stress. They are complex neurological disorders tightly linked to the hyperactivity of the trigeminal nerve (nervus trigeminus), along with vascular and neuroinflammatory alterations in the brain. Modern science increasingly describes a concept known as Clinical Endocannabinoid Deficiency (CECD). Research shows that individuals suffering from migraines exhibit significantly lower levels of their own endocannabinoids, particularly anandamide, in their cerebrospinal fluid. Their brains have a lowered threshold of sensitivity, making them highly vulnerable to pain triggers.In these cases, medical cannabis acts as a targeted substitution therapy, intervening across multiple levels:

• Halting Migraine Aura: Aura – such as visual disturbances (blind spots, flashing zigzag lines) – is driven by an electrochemical wave rolling across the cerebral cortex, known as Cortical Spreading Depression (CSD), which is propelled by an excess of glutamate. By activating CB1 receptors, phytocannabinoids dampen this toxic glutamate flood, effectively stopping the developing attack right at its inception.
• Blocking CGRP Release: The neuropeptide CGRP causes massive vasodilation and neurogenic inflammation of the vessels within the meninges. Modern biological migraine therapies work by blocking this specific peptide. Research confirms that activated CB1 receptors on the trigeminal nerve endings achieve the exact same result – they reduce CGRP release, suppress neurogenic vascular inflammation, and block the transmission of pain signals to the brain's higher centers.
• Ending Nausea and Suffering: Migraines are notoriously accompanied by debilitating nausea, vomiting, and photophobia (sensitivity to light). Through interaction with serotonin receptors in the medulla oblongata, cannabinoids act as a potent antiemetic – eliminating the urge to vomit and calming the gastrointestinal tract in a way that standard over-the-counter painkillers cannot. This exact effect is also heavily utilized to assist oncological patients battling chemotherapy-induced nausea.

Clinical Data: The Power of the THC and CBD Combination

Observational studies reveal that patients experience an average reduction in headache and migraine intensity of nearly 50% following the use of medical cannabis. From a clinical perspective, however, the specific ratio of the two primary compounds is crucial. Recent clinical trials have shown that isolated CBD oils purchased over the internet are generally insufficient to manage acute pain, let alone a fully developed migraine. The highest medical efficacy is consistently demonstrated by a balanced combination of THC and CBD, where THC blocks acute pain transmission and CBD targets inflammatory processes while easing secondary anxiety.Furthermore, I always warn patients in my clinic about the risk of Medication Overuse Headache (MOH). While this vicious cycle develops incredibly fast with the frequent use of standard triptans and classic analgesics, the risk is significantly lower under the controlled, expert supervision of a neurologist utilizing medical cannabis.

My Experience in the Clinic: What Does Personalized Care Look Like?

When a patient arrives at my neurological clinic in Brno, I never prescribe cannabis blindly. Most often, these are individuals who have been treated long-term for intractable symptoms, such as severe neuropathic pain. Prescription decision-making in modern neurology is a strictly individualized process built upon seven critical pillars:

1. Diagnosis and Indication Criteria: I initiate cannabis therapy where it has the strongest backing in medical evidence. The diagnoses where my patients see the most profound benefits include chronic neuropathic pain (e.g., diabetic neuropathy), severe spasticity (post-stroke or multiple sclerosis), intractable post-herpetic neuralgia, trigeminal neuralgia, tinnitus (ringing in the ears), migraines, severe sleep disorders, and the secondary anxiety that heavily complicates chronic neurological illnesses.
2. History of Prior Treatments: Cannabis stands as a second- or third-line therapy – meaning it is introduced when conventional pharmacotherapy has failed, yielded insufficient results, or burdened the patient with intolerable side effects. It is also indicated when standard pharmaceuticals are entirely ruled out due to a patient's severe comorbidities, leaving cannabis as the only safe option within a careful risk/benefit assessment.
3. Thorough Evaluation of Comorbidities: I must have an absolute understanding of the patient's entire health profile. We closely monitor the cardiovascular system (ensuring the patient does not suffer from severe cardiac arrhythmias) and hepatic functions, as cannabinoids are heavily metabolized via the cytochrome P450 enzyme pathway in the liver.
4. Managing Risk Factors (Drug-to-Drug Interactions): I meticulously analyze the patient's entire medication cocktail. Cannabis can alter the blood concentrations and efficacy of other critical drugs, such as warfarin (blood thinners), antiarrhythmics, or antiepileptics. All of these steps are routinely cross-consulted with the patient's treating cardiologist, hematologist, or psychiatrist.
5. Managing Patient Expectations: I maintain a completely transparent dialogue with my patients. Cannabis will not reverse structural brain damage or instantly cure an underlying disease. The objective is a significant reduction of disabling symptoms and a substantial restoration of quality of life.
6. Safety Framework: Establishing rigid guidelines for usage. Patients are thoroughly educated on how the medication behaves in the body, the strict prohibition of driving motor vehicles after use, and how to manage and prevent any temporary psychological discomfort.
7. Systematic Monitoring of Efficacy: Patients maintain a detailed treatment diary, tracking their pain scales, muscle tension, sleep quality, and any potential side effects. This data allows us to make exact, evidence-based adjustments during follow-up consultations.

Which Forms Are Utilized in Neurology?

Step away from the medicine cabinets filled with unverified, non-standardized CBD oils from e-shops. In clinical medicine, we strictly use standardized, pharmaceutical-grade forms:

• Medicinal Dry Flower (Sušina): Contains a precise, laboratory-guaranteed ratio of THC and CBD. It is utilized either via vaporization (inhaling a clean, microscopic vapor using certified medical vaporizers, completely free of combustion, tar, and smoke) or it is sent for further compounding into capsules.
• Extracts and Oral Kapsules: Oral capsules are exceptionally popular in my practice. The raw flower undergoes a thermal process known as decarboxylation in the pharmacy laboratory, which chemically activates the cannabinoids. A master pharmacist then encapsulates it into miligram-precise doses.

The absolute key to therapeutic success is dose titration, governed by the golden rule: "start low, go slow." We begin treatment with minimal micro-doses taken exclusively in the evening and gradually elevate the dosage over several weeks based on individual tolerance and effect. The goal is to lock into the perfect therapeutic window – a state where symptoms disappear and side effects are completely non-existent.

Patient Manual: How Does Legal Treatment Work in the Czech Republic?

The Czech Republic possesses one of the most progressive medical cannabis legislations in Europe. Public health insurance companies in the Czech Republic cover a massive 90% of the cost of medical cannabis. This coverage is guaranteed by law; consequently, a patient pays a copayment of only the remaining 10% at the pharmacy counter (up to a legal limit of 30 grams of dry flower or its extract equivalent per month). Furthermore, the legislation allows doctors to issue prescriptions for up to a 3-month supply, saving patients valuable time. Medical cannabis prescription has also been newly extended to qualified general practitioners.Yet, a glaring Czech legislative paradox remains. Prescription rates among physicians are still exceptionally low. While global clinical trials from Israel or Canada are moving cannabinoids into first-line standard care, Czech patients routinely face reluctance. The root cause is a psychological barrier – doctors' fear of administrative burdens, the intricate data entry required for specialized e-prescriptions, and a lingering historical stigma. Sadly, patients using legal cannabis face this stigma even from other medical professionals who mislabel them, failing to distinguish a strictly monitored, highly controlled medical treatment from illicit recreational substance abuse.

If you are considering this treatment, here is a step-by-step administrative guide on how the process unfolds through a neurologist:

• Indication: The neurologist verifies that your clinical diagnosis satisfies the strict legal and medical conditions required for a medical cannabis prescription.
• Documentation: The physician enters a comprehensive, legally mandated justification for the therapy into your medical records.
• e-Prescription: A highly specialized electronic prescription is issued (a magistraliter prescription for a controlled substance). It contains a unique code designating the exact THC/CBD ratio and the pharmaceutical form the pharmacist must compound (e.g., capsules, ointments). It is classified as an individually prepared medicinal product (IPLP).
• Pharmacies and Availability: You bring this prescription to a pharmacy licensed to compound cannabis products. While the overall availability of medical cannabis flower and extracts in the Czech Republic is currently excellent, it is important to remember that only select pharmacies maintain physical stock. Cannabis must still be treated as a highly regulated, controlled substance that requires specialized storage and logging protocols within the pharmacy, identical to medical opiates.
• Insurance Coverage: The pharmacy scans the e-prescription, and the system automatically applies the 90% health insurance coverage. You only cover the minimal remaining copayment. Note: This insurance coverage does not apply if your prescription is written by a private, non-contracted physician who does not have an active agreement with your public health insurance provider.
• Safety Monitoring: You will attend regular follow-up appointments where the physician closely evaluates your treatment tolerance, checks for side effects, and adjusts the milligram dosage as needed.
• Travel Notice: If a patient is planning to travel abroad, they must verify whether medical cannabis is fully legal in the destination country. If it is not, the treatment can be safely discontinued prior to travel without the development of severe withdrawal symptoms.

What Medical Cannabis Is NOT

To maintain absolute scientific and professional integrity (evidence-based medicine), we must clearly delineate what cannabis cannot achieve:

• It is not a miracle cure-all: Cannabis will not cure the underlying pathology of multiple sclerosis, nor will it resurrect dead brain tissue following an ischemic stroke. It is an exceptionally potent symptomatic treatment, and intensive global research continues daily to map its exact pathways and therapeutic boundaries.
• It is not a replacement for conventional therapy: In neurology, it operates strictly as an add-on therapy (a complementary tool). It never replaces disease-modifying therapies or mandatory primary medications (such as anti-seizure drugs).
• It is not for acute emergencies: Pharmacy-compounded capsules cannot stop an active, acute epileptic seizure or treat an ongoing stroke in an emergency room. It belongs exclusively in the realm of chronic care.
• It is strictly contraindicated in psychosis: For individuals with a personal or strong family history of schizophrenia or bipolar disorder, the administration of cannabis (specifically the THC component) is strictly prohibited, as it could unmask or severely exacerbate psychotic episodes.
• It is not a "natural alternative" from the market: Medical cannabis is subjected to the exact same chemical standardization as any other pharmaceutical molecule. This is not folk herbalism; it is exact phytofarmacotherapy.

Conclusion: Neurology Without Dogma

Modern neurology evaluates human health through the lens of hard data, clinical trials, and real-world patient outcomes. The prevailing European trend is a clear, decisive shift away from historical stigma and toward pragmatic medical reality.Medical cannabis is neither an alternative miracle nor charlatanism. It is a symptomatic, safe, and state-monitored medical treatment that, in the hands of an experienced neurologist, can offer profound relief where conventional options have completely failed. To ignore this tool today does not make a physician cautious. It means choosing to stay behind, directly at the expense of our patients' quality of life. Prejudices have no place in modern medicine.Disclaimer: This article is for informational purposes only and does not replace professional medical advice. The suitability and indication of medical cannabis treatment must always be evaluated individually by your attending physician based on your overall health status and current legislation.

MUDr. Petra Mištríková, MBA
Neurologie Mištríková, Neurologická ambulance pro dospělé s.r.o.

Neuro-microclinic in Brno. Neurology with mind and heart.

References:

Wences Chirino, T.; Rangel López, E.; Luna Angulo, A.; Carrillo Mora, P.; Landa Solis, C.; Samudio Cruz, M.A.; Fuentes Bello, A.C.; Paniagua Pérez, R.; Ríos Martínez, J.; Sánchez Chapul, L. Crosstalk between Exercise-Derived Endocannabinoidome and Kynurenines: Potential Target Therapies for Obesity and Depression Symptoms. Pharmaceuticals 2023, 16, 1421. https://doi.org/10.3390/ph16101421

Aliuș C, Breazu A, Pantu C, Toader C, Șerban M, Covache-Busuioc RA, Munteanu O, Dumitru AV. The Endocannabinoid-Microbiota-Neuroimmune Super-System: A Unifying Feedback Architecture for Systems Resilience, Collapse Trajectories, and Precision Feedback Medicine. Int J Mol Sci. 2025 Nov 12;26(22):10959. doi: 10.3390/ijms262210959. PMID: 41303442; PMCID: PMC12652726.

Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016 Jul 1;1(1):154-165. doi: 10.1089/can.2016.0009. PMID: 28861491; PMCID: PMC5576607.

Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):31-9. PMID: 15159679.

Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):31-9. PMID: 15159679.

Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016 Jul 1;1(1):154-165. doi: 10.1089/can.2016.0009. PMID: 28861491; PMCID: PMC5576607.

Lochte BC, Beletsky A, Samuel NK, Grant I. The Use of Cannabis for Headache Disorders. Cannabis Cannabinoid Res. 2017 Apr 1;2(1):61-71. doi: 10.1089/can.2016.0033. PMID: 28861505; PMCID: PMC5436334.

https://www.cannaspecialists.org/cannabinoids_and_migraines_emerging_evidence_and_clinical_implications